Thioridazine, 1789t, 1797t, 1799t

for schizophrenia, 1788

Thiotepa, 469t, 2004

neurotoxicity of, 1985t

Thiothixene, 1789t, 1797t, 1799t

Thioxanthene, 1789t

Thiram, 822t

Third-generation cephalosporin (TGC)

for aerobic gram-positive cocci, 1326t

for gram-negative aerobes, 1327t

3-hydroxy-3-methyl-glutaryl coenzyme A inhibitors

adverse effects, 116–118

clinical pearls, 120–121

diabetes, 118–119

drug interactions, 119–120

efficacy, 115–116

mechanism of action, 115

pharmacokinetics/pharmacodynamics, 116

place in therapy, 119

reaction catalyzed by, 116f

3,4-methylenedioxymethamphetamine (MDMA; Ecstasy), 1885

3tC (see Lamivudine)

Thymoglobulin and antithymocyte globulin, 725–726

Thymol, 1626

Thyrotropin-α, 1069

Tiagabine, 1279t, 1281, 1845

for seizures, 1285t, 1286

Tianeptine, 1856

Ticagrelor, 246–247t

and aspirin, for ACS, 242t

Ticarcillin, 583t

for cystic fibrosis, 461t

Ticlopidine, 1307t, 1314

for diabetes, 168

for PAD, 168

Tigecycline, 1325t

for aerobic gram-positive cocci, 1326t

dosing of, 1338t

for gram-negative aerobes, 1327t

Timentin, 1325t

for aerobic gram-positive cocci, 1326t

for gram-negative aerobes, 1327t

Timolol, 2261t

for glaucoma, 1150

for MI, 253

Timoptic, 1150 (see also Timolol)

Timoptic XE, 1151

Tindamax (see Tinidazole)

Tinidazole, 1706

for amebic liver abscess, 1704t

for gastrointestinal disease, 1704t

for giardiasis, 1703t

for trichomoniasis, 1526–1527

Tinzaparin, 177t, 188t

LMWH, 656

Tioconazole, 1624t

Tiotropium, 420t, 421–423

Tiotropium plus olodaterol

for COPD, 421

Tipiracil, 470t

Tipranavir (TPV), 120t, 914t, 942t, 1580t

Tirofiban, 237

Tissue amebicide, 1706

Titanium dioxide, 849t

TIV (see Trivalent inactivated vaccine (TIV))

Tizanidine, 942t, 1186t, 1224

drug interaction with smoking, 1906t

TKIs (see Tyrosine kinase inhibitors (TKIs))

TMP (see Trimethoprim (TMP))

TMP-SMX (see Trimethoprim-sulfamethoxazole (TMP-SMX))

TNF-α inhibitors, for psoriasis, 842–843

TNK (see Tenecteplase (TNK))

Tobacco, 1948–1949

TOBI podhaler, 462–463

Tobramycin (Nebcin), 460, 462, 1325t, 1724

adverse effects of, 1332t

for CAPD-associated peritonitis, 1476t

for CNS infections, 1373t

for cystic fibrosis, 461t

dosing of, 1339t

for gram-negative aerobes, 1327t

for inhalation, 462–463

for UTI, 1497t

Tobramycin Podhaler, 461t

Tocilizumab, 881, 883, 896t, 897, 899, 903–904

Tofacitinib, 882

Toki-shakuyaju-san, 1015

Tolbutamide, 1140

Tolcapone (Tasmar), 1251t

pharmacologic and pharmacokinetic properties of, 1263t

Tolindate, 1626

Tolmetin, 870t, 888t

Tolnaftate, 1624t

Tolterodine tartrate, 2251

Tolvaptan, 128

for HF, 267

for hyponatremia, 579

Tonabersat, 1242

Topamax (see Topiramate)

Topical protectants, for burn injuries, 863

Topical steroids, 523

Topiramate, 942t, 1181t, 1242, 1244, 1271t, 1272, 1279t, 1281, 1845, 1900–1902

for ASD, 1856

for diabetes, 1145

for seizures, 1285t, 1286

teratogenic effects, 973t

Topotecan, 128, 469t, 470t, 1991t

Torsemide, 647, 580

for HF, 277

Toujeo (see Insulin glargine)

Toxin binders

for CDAD, 1466

TPV (see Tipranavir (TPV))

Trabectedin, 469t

Tramadol, 867, 1182t

for diabetes, 1145

for OA, 872

Trametinib, 470t

Trandate (see Labetalol)

Trandolapril, 281, 281t

in hypertension, 153t

Tranexamic acid, 942t

Tranquilizers, 552

Transdermal fentanyl

dosage of, 1199–1201

transition to, 1201

Transderm-Scop (see Scopolamine)

Tranylcypromine, 1751

Trastuzumab (Herceptin), 469t, 475, 1982t, 1987, 1989

for breast cancer, 2053, 2057

Travasol, 794t

Travatan (see Travoprost)

Travoprost (Travatan), 1151

Trazodone, 1769, 1827

for agitated behaviors, 2243

for serotonin, 1826

and sexual response, 2261t

and sleep, 1774

for sleep, 1861

Treanda (see Bendamustine)

Treprostinil, 924

Tresiba (see Insulin degludec)

Tretinoin, 470t, 827, 858

for AML, 2027

Trexall (see Methotrexate)

Triacetin, 1626

Triamcinolone, 442

Triamcinolone acetonide (Nasacort AQ), 441t

Triamterene, 543, 580–581

and hyperkalemia, 585

for hypertension, 148

Triazolam (Halcion), 1737t, 1767–1768

for treatment of insomnia, 1767t

Triazoles, 1624, 1625, 1636, 1637, 1639

Trichloroacetic acid, 1532

Tricyclic antidepressants (TCAs), 71, 77–78, 942t, 1261t, 1856

for ADHD, 1871

for anxiety disorders, 1748

for critically ill patients, 1208

drug interaction with smoking, 1907t

GERD and, 503t

for pain management, 1188, 1189, 1195

for panic disorder, 1748

for PTSD, 1754

and sexual response, 2261t

Tridil (see Nitroglycerin)

Trifluoperazine, 1789t, 1797t, 1799t

Trifluridine, 470t, 1167, 1647t

for adverse effects, 2081

Trihexyphenidyl, 1250t

p. 2316

p. 2317

for Akathisia, 1800t

for Parkinsonism, 1799

Triiodothyronine, 1049

Trileptal (see Oxcarbazepine)

Trimethoprim (Trimpex; TMP), 973t, 1326t, 1370

for chronic antimicrobial therapy, 1499t

for cystic fibrosis, 461t

sulfamethoxazole and, 1499t

for UTI, 1489t

Trimethoprim-sulfamethoxazole (Bactrim; Septra; TMP-SMX), 418, 828, 1326t, 1368, 2009

alternatives, 1603–1604

for CNS infections, 1373t

for cystitis, 1489

dosing of, 1339t

hematologic side effects, 1603

hypersensitivity (skin rash) reaction, 1603

for OIs, 1602–1603

for PJP, 1602–1603

for skin and soft tissue infections, 1547

for toxoplasmosis, 1606

for UTI, 1489t

Trimpex (see Trimethoprim)

Triptans, 1237

dosing and comparative pharmacokinetic parameters of, 1238t

second-generation, 1239

Trisodium citrate, 656

Trivalent inactivated vaccine (TIV), 1361

Trolamine salicylate, 849t

TrophAmine, 2150, 2152

Troponin, 233, 235

Trospium chloride, 2251

Trusopt (see Dorzolamide)

Tums, 713–714

Turpentine, 822t

Twinrix, 1356t

Twisthaler, 395

Tykerb (see Lapatinib)

Tyrosine kinase inhibitors (TKIs), 2031

for cancer, 1958–1959

U

Ulipristal, 951

Ultram (see Tramadol)

Ultrarapid opiate detoxification (UROD), 1879

Umeclidinium, 420t

Umeclidinium plus vilanterol, 421

Unasyn, 1325t

for aerobic gram-positive cocci, 1326t

for anaerobes, 1328t

for gram-negative aerobes, 1327t

Undecylenic acid, 1624t

Unipen (see Nafcillin)

Urea, 579, 581

Uricase, 917

UROD (see Ultrarapid opiate detoxification (UROD))

Ursodiol, 2152

Ustekinumab, 842–843

V

Vaccination

for HBV, 1690

hepatitis A vaccine, 1666–1667, 1666t

dosage, 1666, 1666t

with HBV vaccine, 1666

indications for, 1667

hepatitis B vaccines

adverse effects, 1674

dosage, 1673

duration of vaccine-induced immunity, 1673–1674

immune response to, 1673

indications for, 1674

and infants, 1673

with Recombivax HB, 1673

universal, 1674

herpes zoster vaccine (Zostavax), 1652

for Lyme disease, 1721

for malaria, 1701

for OIs, 1598

for prostate cancer, Sipuleucel-T, 2095

teratogenic effects, 973t

Vagifem (see Estradiol hemihydrate tablets)

Vaginal prostaglandin E2, 989

Valacyclovir (Valtrex; VCV), 743, 1648t

adverse effects, 1647t

for genital herpes, 1529–1530, 1530t

for herpes labialis, 1651

for herpes zoster infection, 1652

pharmacokinetics of, 1653t

Valcyte (see Valganciclovir)

Valganciclovir (Valcyte), 743, 1613, 1649t

adjunctive therapy, 1608t

adjusted dosage, 1610t

advantages, 1608t

adverse effects, 1647t

for CMV primary prevention, 1613–1614

for CMV retinitis, 1607, 1609

CrCl, 1610t

disadvantages, 1608t

dosing regimens, 1608t

important drug interactions, 1608t

monitoring requirement, 1609t

normal dosage, 1610t

precautions and contraindications, 1609t

select adverse effects, 1608t

Valproate (VPA), 1242, 1279t, 1837

for absence and primary generalized tonic-clonic seizures, 1292–1294

for absence seizures, 1290–1291, 1291t

adverse effects, 1839–1840

and alopecia, 1840

for bipolar disorder, 1849t

for developmental disorders, 1858

dosage, 1839

and gastrointestinal complaints, 1839

and hyperammonemic encephalopathy, 1840

for mania, 1839–1840

monitoring of, 1839

for seizures, 1284t

and weight gain, 1839–1840

weight gain with, 1839–1840

Valproic acid, 942t, 1837, 2131t

dose–response curve, 972

for schizophrenia, 1809

teratogenic effects, 973t

Valrubicin, 469t

Valsartan, 257

for hypertension, 154t

for treatment of HF, 271

Valtrex (see Valacyclovir)

Vancocin (see Vancomycin)

Vancomycin (Vancocin), 658–659, 661, 662, 693–694, 1326t, 1349, 1371, 1380, 1394

adverse effects of, 1333t

for aerobic gram-positive cocci, 1326t

for anaerobes, 1328t

for CAPD-associated peritonitis, 1476t

for cardiac surgery prophylaxis, 1392

for CDAD, 1465–1466

for CNS infections, 1373t

for CSF shunt infection, 1379

dosing of, 1339t

for enterococcal endocarditis, 1397t

for febrile neutropenia, 1564

gentamicin and, 1398

for HAP, 1418

high-risk medication, 635–636

MRSA, 1550

for MRSA endocarditis, 1394–1396

for NEC, 2183

for PVE, 1392t

renal failure, dosing of drugs, 674–675

for sepsis, 2186t

for skin and soft tissue infections, 1548, 1549

Vandetanib, 470t

Vanillylmandelic acid (VMA), 2003

Vantin (see Cefpodoxime proxetil)

Vaqta, 1357

Vardenafil, 2265

and ED, 2265

Varenicline

adverse reactions, 1920

for depressive disorders, 1815t

dosage, 1920

patient education, 1920

pharmacokinetics, 1920

for smoking cessation, 1909, 1914

Varivax, 1362, 1363

Varubi (see Rolapitant)

Vasepa, 126

Vasodilators

for ACS, 247–248

for IC, 168–169

Vasopressin, 547, 2207t, 2208

for cardiopulmonary arrest, 330–331

for postoperative cardiac failure, 363t

for septic shock, 371

in treatment of IDH, 657

Vasopressin receptor antagonists (VRAs), 579–580

Vasotec IV (see Enalaprilat)

VCV (see Valacyclovir (VCV))

Vecuronium, 2200t

p. 2317

p. 2318

Vedolizumab

for CD, 527–528

for inflammatory bowel disease, 522t

for UC, 527–528, 529

Velban (see Vinblastine)

Velcade (see Bortezomib)

Vemurafenib, 470t

Venetoclax, 470t

Venlafaxine (Effexor, Effexor XR), 1027t, 1182t, 1188, 1238, 1245, 1738t, 1986

androgen deprivation therapy, 2097

for depressive disorders, 1819t, 1820t

for diabetes, 2226t

for panic disorder, 1748

for serotonin, 1826

for vasomotor symptoms, 1036t

Venlafaxine ER, 1821t

Venlafaxine IR

for depressive disorders, 1821t

for hot flushes, 1036

for PMDD, 1025

Venlafaxine XR 1738t, 1748, 1751, 1752

for PTSD, 1754

for SAD, 1752

Venofer (see Iron sucrose)

VePeSid (see Etoposide)

Verapamil, 120t, 128, 155, 169, 214, 609, 1061, 1244, 2261t

for AF, 314

for HF, 275

for HFpEF, 271, 272

for nocturnal leg cramps, 173

in patients with CKD, 617

for thyroid storm, 1067

Vesanoid (see Tretinoin)

Vibativ (see Telavancin)

Viberzi (see Eluxadoline)

Vidarabine, 1648

for herpes encephalitis, 1646

Vigabatrin, 1279t

Vilanterol, 420t, 421

Vilazodone, 1827

for depressive disorders, 1819t, 1821t

Vinblastine, 469t, 1978–1979t, 1981t, 1996t, 2040t

and autonomic neuropathy, 1987

and cranial neuropathies, 1987

gonadal toxicity of, 1998

neurotoxicity of, 1985t

peripheral nerve toxicity of, 1986

Vinca alkaloids, 1981t

gonadal toxicity of, 1998

Vincristine, 469t, 1979t, 1981t, 1987, 2005, 2040t, 2042

for ALL, 2017t

and autonomic neuropathy, 1987, 2015

for HL, 2041

intrathecal, problems of, 2016

neurotoxicity of, 1985–1986, 1985t

peripheral nerve toxicity of, 1986

for rhabdomyosarcoma, 2010, 2011

for T-cell lymphomas, 2020t

Vindesine, 1979t

Vinorelbine, 469t, 1979t

neurotoxicity of, 1985t

for NSCLC, 2062t, 2064t

peripheral nerve toxicity of, 1986

Virazole (see Ribavirin)

Vismodegib, 470t

Vistaril (see Hydroxyzine)

Vistide (see Cidofovir)

Vitamin A, 612

and pregnancy, 968

teratogenic effects, 973t

Vitamin B, 1015

Vitamin B6

(see Pyridoxine)

Vitamin B12

, 486

for pernicious anemia, 1935

Vitamin C (see Ascorbic acid)

Vitamin D

for endometriosis, 1021

nutritional vitamin D, 621

and pregnancy, 968

for pulmonary exacerbations, 454

receptor agonist, 621–622

calcitriol, 621–622

doxercalciferol, 622

paricalcitol, 622

Vitamin E, 657–658, 961, 1015, 1986

for diabetic neuropathy, 1986

for dysmenorrhea, 1015

and pregnancy, 968

for prostate cancer, 2099

Vitamin K

dependent clotting factors, 180t

and pregnancy, 968

for pulmonary exacerbations, 454

supplementation in pregnant women, 1298

warfarin and, 195–196

VMA (see Vanillylmandelic acid (VMA))

Vorapaxar, 169, 244

for ACS, 243t

Voriconazole, 59, 120t, 128, 942t, 1569, 1624, 1624t, 1625, 1628, 1633, 1634, 1639

adverse effects, 1334t, 1639

dosing of, 1339t

Vorinostat, 470t

Vortioxetine, 1827

for depressive disorders, 1819t, 1821t

Votrient (see Pazopanib)

VPA (see Valproate)

Vraylar (see Cariprazine)

W

Warfarin, 41, 42–43, 44, 54–55, 95, 128, 204, 484, 485, 486, 942t, 1307t, 1314–1315

for ACS, 243t, 258–259

action of, 180f

adverse effects of, 194

alcohol ingestion and, 196–197

anticoagulant therapy, 192

and clotting factors, 1057

dosing adjustments, 197, 197t

drug interactions with, 203–205, 204t

drug interaction with smoking, 1907t

effects of, 192t

factors influence, 195–197

frequency of follow-up, 197

genetic factors and, 197

hemorrhage from, 194

initiation dosing algorithm, 193f

intensity and duration of, 193–194

interactions with disease states, 196t

international normalized ratio monitoring, 198t

overanticoagulation, management of, 197–198

in pregnancy, 198–200

protocol for, 193t

purple toe syndrome from, 194

skin necrosis from, 194

for stroke prophylaxis, 2242

teratogenic effects, 973t

therapy, initiation of, 192–193